IR-MED Names Moshe Gerber as CEO

IR-Med has a new leader.

The company has appointed Moshe Gerber as CEO. “Moshe’s focus on deal-making and international growth in the medical device sector makes him the ideal executive to lead IR-Med’s business plan forward”, said Oded Bashan, IR-Med’s board chairperson. “He is a highly accomplished executive with a strong track record of execution, innovation and success.” 
 
Gerber brings to his new position more than 25 years’ experience in international business development, sales and operations across high-tech industries, including artificial intelligence (AI), software, and medical devices, with wide ranging experience in product strategy and market analysis, of which 10 years’ experience was in leading roles at several companies in the medical devices industry. Between 2011 and 2015, Moshe established and managed a medical device company—Gerium Medical—which developed a product for jaundice measurement. Gerber subsequently orchestrated the sale of his company to Mennen Medical, a private firm that develops and sells medical devices for hospitals worldwide via offices in United States, United Kingdom, and Israel. Gerber then served as vice president of Business Development and Sales at Mennen Medical, managing business development, marketing and sales activities through a direct sales force and worldwide distributors.

Gerber earned MBA from San Jose State University in California, and B.Sc. in mathematics and computer science from Tel-Aviv University.
 
“I am deeply humbled and honored to be taking on this role and lead IR-Med and our team” Gerber said, “IR-Med has a unique market position that serves as a benefit to targeted users of our product candidates. It is my responsibility to combine our scientific work while driving enhanced returns for shareholders. I am thrilled to present the world with our disruptive technologies and their promise.”
 
IR-MED Inc. is developing a non-invasive spectrographic analysis technology platform, allowing healthcare professions to detect and measure different molecules in the blood and in human tissue in real-time without any invasive procedures. The first product under development is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, regardless of skin tone and which calibrated personally to each patient’s skin, primarily caused by prolonged pressure associated with bed confinement. IR-MED skin-device-interphase development of personalized medical devices allows high accuracy readings from the human body in a non-invasive method, that may provide caregiver the optimal decision support-system in cases where uncertainties disturb physicians in their decision processes.
 
IR-MED holds patents protecting its innovation in the noninvasive tissue analysis, and in the modeling and analysis of subcutaneous tissue.